This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.

Inclusion Criteria:

• Age at least 18 years.
• Pathologically confirmed diagnosis of a solid tumor cancer.
• Patients receiving treatment with immune checkpoint inhibitors.
• Ability to understand and willingness to provide the informed consent.

Exclusion Criteria:

• Age < 18 years.
• Patients with hematological malignancies or solid benign tumors.
• Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.

Adult patients with solid tumors treated with immune-checkpoints inhibitors